Comparing Aromasin vs Sacituzumab Govitecan
| Aromasin (exemestane) | Sacituzumab govitecan |
|
|---|
| Aromasin (exemestane) | Sacituzumab govitecan |
|
|||||||
|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Aromasin is a brand (trade) name for exemestane which is a medication that is used to treat breast cancer in postmenopausal women. It is often given to women whose cancer has progressed despite... View more |
Prescription only
Prescribed for Breast Cancer. Sacituzumab govitecan may also be used for purposes not listed in this medication guide. |
Related suggestions Breast Cancer
|
|||||||
| More about Aromasin (exemestane) | More about Sacituzumab govitecan | ||||||||
| Ratings & Reviews | |||||||||
|
Aromasin has an average rating of 4.9 out of 10 from a total of 24 ratings on Drugs.com. 25% of reviewers reported a positive effect, while 38% reported a negative effect. |
Sacituzumab govitecan has an average rating of 7.4 out of 10 from a total of 5 ratings on Drugs.com. 80% of reviewers reported a positive effect, while 20% reported a negative effect. |
||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | |||||||||
|
View all Aromasin side effects |
View all Sacituzumab govitecan side effects |
||||||||
| Drug Class | |||||||||
| Generic Availability | |||||||||
|
N/A |
|||||||||
| Pricing and Coupons * Prices are without insurance | |||||||||
View all Aromasin prices |
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
||||||||
| Dosage Forms | |||||||||
|
N/A |
||||||||
| Brand Names | |||||||||
|
N/A |
Trodelvy | ||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | |||||||||
|
24 hours |
18 hours |
||||||||
| CSA Schedule 1 View glossary of CSA terms | |||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||
| Pregnancy Category | |||||||||
|
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||
| Drug Interactions | |||||||||
|
A total of 100 drugs are known to interact with Aromasin:
|
A total of 231 drugs are known to interact with Sacituzumab govitecan:
|
||||||||
| Alcohol/Food/Lifestyle Interactions | |||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||
| Disease Interactions | |||||||||
| First Approval Date | |||||||||
|
October 21, 1999 |
April 22, 2020 |
||||||||
| WADA Class View classifications | |||||||||
|
N/A |
|||||||||
| More Information | |||||||||
| Patient Resources | |||||||||
| Professional Resources | |||||||||
| Related Treatment Guide | |||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.